KIR2DS2 / CD158J antibody

Principal name

KIR2DS2 / CD158J antibody

Alternative names for KIR2DS2 / CD158J antibody

NKAT5, CD158 antigen-like family member J, MHC class I NK cell receptor, NK receptor 183 ActI, Natural killer-associated transcript 5, NKAT-5, p58 natural killer cell receptor clone CL-49, p58 NK receptor CL-49, Killer cell immunoglobulin-like receptor 2DS2

Gene ID

100132285 (KIR2DS2)

Ncbi ID


Available reactivities

Hu (Human)

Available hosts


Available applications

Western blot / Immunoblot (WB)

Background of KIR2DS2 / CD158J antibody

Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by tural killer cells and subsets of T cells (1). The KIR proteins are classified by the number of extracellular immunoglobulin domains and by whether they have a long (L) or short (S) cytoplasmic domain (2,3). KIR proteins are thought to play an important role in regulation of the immune response (3). KIR2DS2 downregulates the cytotoxicity of NK cells upon recognition of specific class I major histocompatibility complex (MHC) molecules on target cells and is a receptor on tural killer (NK) cells for HLA-C alleles (3,4).

2 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

KIR2DS2 / CD158J antibody

  Rabbit Polyclonal Anti-KIR2DS2 Antibody  
Western blot analysis of KIR2DS2 in 293 cell lysate with KIR2DS2 antibody at (A) 1 and (B) 2 ug/mL. Rabbit IgG Purified Hu WB
0.1 mg / €382.00
  OriGene Technologies, Inc.

Proteins & Growth Factors

Catalog No. Species Pres. Purity Source  

KIR2DS2 / CD158J

  Recombinant protein of human killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 (KIR2DS2)  
KIR2DS2 / CD158J Human > 80 %
Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps.
Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining.
HEK293 cells
20 µg / €680.00
  OriGene Technologies, Inc.

2 Item(s)

per page
  • LinkedIn